Endoluten
Anti-Aging / CircadianAlso known as: Pineal peptide complex
Mechanism
An oral peptide complex derived from pineal gland extract. It restores melatonin secretion and circadian rhythm regulation. Considered the "master" bioregulator in Khavinson's framework because disrupted circadian rhythms affect every organ system. Khavinson's own longevity research centers heavily on pineal peptides (Epithalon is the synthetic version, Endoluten is the natural extract form).
Technical detail
Peptide complex isolated from animal pineal gland, containing short peptides with proposed epigenetic activity on pinealocytes. Restores rhythmic melatonin production by modulating expression of AANAT (arylalkylamine N-acetyltransferase) and ASMT (acetylserotonin O-methyltransferase) — the rate-limiting enzymes in melatonin synthesis. In Khavinson's framework, the pineal gland is the master regulator of aging; declining melatonin disrupts circadian gene expression (CLOCK, BMAL1, PER, CRY) throughout the body. Endoluten is the natural-extract counterpart to Epithalon (Ala-Glu-Asp-Gly), which activates telomerase. Russian clinical data: elderly patients showed restored circadian cortisol rhythm and improved sleep architecture.
Effects
NEUROLOGICAL/CIRCADIAN: Primary target is the pineal gland. Restores melatonin synthesis in aging pineal tissue by upregulating serotonin N-acetyltransferase (AANAT) and hydroxyindole O-methyltransferase (HIOMT) — the rate-limiting enzymes for melatonin production (animal, Khavinson studies). Normalizes circadian rhythm architecture in elderly subjects with documented melatonin decline (Russian clinical series, n=34). Improves sleep latency, sleep efficiency, and subjective sleep quality in aged subjects (Russian clinical data, Tier 3). Restores pinealocyte ultrastructure in aged rats — reversed lipofuscin accumulation and mitochondrial degeneration (animal: Khavinson et al.). ENDOCRINE: Restores the circadian cortisol-melatonin axis. Downstream effects on growth hormone secretion (GH pulse amplitude is coupled to deep sleep, which depends on melatonin signaling). Normalizes circadian TSH rhythm disrupted in aging. May restore circadian insulin sensitivity cycling (theoretical, based on melatonin-insulin interaction). IMMUNE: Melatonin restoration has broad immunomodulatory effects — melatonin enhances NK cell activity, T-helper cell function, and antibody production (established melatonin literature, RCTs). Pineal-thymus axis: Khavinson demonstrated bidirectional signaling between pineal and thymus; pineal restoration supports thymic function (animal). MUSCULOSKELETAL: Indirect via improved sleep architecture — deep sleep is when GH secretion peaks and tissue repair occurs. Better circadian function supports muscle protein synthesis timing. CARDIOVASCULAR: Melatonin is cardioprotective — antioxidant, anti-inflammatory, improves endothelial function. Restoration of endogenous melatonin rhythm may be superior to exogenous melatonin supplementation for cardiovascular protection (theoretical, Tier 3 practitioner hypothesis). NEUROLOGICAL (Beyond Circadian): Khavinson bioregulator peptides are theorized to interact with DNA at promoter regions, modulating gene expression epigenetically (Khavinson peptide-DNA interaction studies, in vitro). May protect pinealocytes from age-related calcification. METABOLIC: Circadian disruption is independently associated with obesity, diabetes, and metabolic syndrome. Restoring pineal function theoretically addresses root cause of age-related circadian metabolic dysfunction. SKIN: Melatonin is a potent skin antioxidant; restoring endogenous production supports UV repair mechanisms. GI: Melatonin is produced in GI tract in quantities 400x greater than pineal — enteric effects not directly addressed by pineal bioregulation. Tier 3: Khavinson clinical studies in elderly patients (>60 years) showed restoration of melatonin levels to 60-80% of youthful values after 3-month treatment course. Practitioner observations note improved sleep quality within 2-4 weeks, with sustained benefits for 3-6 months after completing a course.
Practitioner Guide
DOSING TIPS: Standard Khavinson protocol: 1-2 capsules (10-20mg) daily for 30 days, repeated 2-3 times per year. Taken orally as enteric-coated capsules. Unlike exogenous melatonin, Endoluten works by restoring the gland's own production capacity — onset is gradual (1-3 weeks) rather than immediate. Do not expect the same-night effect of melatonin supplementation. TIMING: Take in the evening, 1-2 hours before desired sleep time, to align with natural pineal activation period. Some practitioners split dose: 1 capsule morning, 1 evening for overall pineal support. SUPPLEMENT SYNERGIES: Combine with Epithalon for the Khavinson "anti-aging doublet" — Epithalon activates telomerase while Endoluten restores pineal function. Thymalin completes the "Khavinson triad" (pineal + thymus + telomeres). Ensure adequate tryptophan intake (precursor to serotonin→melatonin pathway). Vitamin B6 (P5P form) is a cofactor for serotonin synthesis. Magnesium glycinate supports melatonin production and GABA activity. Zinc is required for melatonin synthesis. Avoid blue light exposure in evening to not counteract Endoluten's effects. CYCLING: Strict course-based protocol — 30 days on, then off for 3-6 months. This is the Khavinson bioregulator paradigm: short courses that "reprogram" gland function with lasting effects. Do not use continuously. 2-3 courses per year is standard. STACKING: Khavinson triad: Endoluten + Epithalon + Thymalin. For sleep focus: Endoluten + DSIP + magnesium. For comprehensive anti-aging: Endoluten + Epithalon + GHK-Cu + NAD+ precursor. Do not stack with high-dose exogenous melatonin — the goal is to restore endogenous production. Low-dose melatonin (0.3-0.5mg) may be used during the first week while Endoluten takes effect. CONTRAINDICATION NUANCES: Avoid in autoimmune conditions where melatonin modulation could be problematic (some autoimmune diseases are worsened by immune stimulation). Patients on immunosuppressants should use with caution. Not studied in pregnant or lactating women. May interact with blood thinners (melatonin has mild antiplatelet effects). STORAGE: Room temperature, away from light and moisture. Shelf life 2-3 years in original packaging. COMPOUNDING: Not typically compounded; obtained as manufactured product from European/Russian suppliers (Peptide Bioregulator brand). Quality varies significantly between sources — advise patients to source from established suppliers. PATIENT EDUCATION: Explain that this is not melatonin — it is a bioregulator that helps the pineal gland make its own melatonin again. Effects build over 2-4 weeks. The goal is to restore the body's own circadian rhythm rather than depending on external melatonin. Sleep improvements may be subtle at first — track with sleep diary or wearable. Best suited for patients over 40 whose melatonin production has measurably declined. Tier 4 community intelligence: Biohacking forums report best results in patients 50+ with documented low melatonin; younger patients with intact pineal function may not notice significant benefit.
Research Summary
TIER 1 (Gold Standard): No Western RCTs exist for Endoluten specifically. The underlying science of melatonin's role in aging, immunity, and circadian regulation is supported by extensive Tier 1 evidence (Claustrat et al., 2005, PMID: 16183237; Pandi-Perumal et al., 2006). TIER 2 (Strong): Khavinson VK et al., multiple publications on peptide bioregulators and pineal function (reviewed in Advances in Gerontology, 2011). Khavinson VK & Anisimov VN — peptide bioregulator effects on aging (Biogerontology, 2003, PMID: 14501183). Peptide-DNA interaction studies showing short peptides can modulate gene expression at promoter regions (Khavinson et al., 2012). TIER 3 (Moderate): Russian clinical series (n=34 elderly patients) showing melatonin restoration and improved sleep parameters after Endoluten course (Khavinson, unpublished but cited in reviews). Practitioner case series from European anti-aging clinics documenting improved sleep quality scores and restored circadian cortisol patterns. Conference presentations at European anti-aging medicine congresses. Post-marketing surveillance data from Russia and CIS countries spanning 10+ years. International pharmacopoeia data from Russian registration. Practitioner-reported outcomes: sleep improvement in 65-80% of patients over 40 (multiple clinic series, not peer-reviewed). KEY FINDINGS: (1) The concept of restoring endogenous gland function via bioregulatory peptides is unique and theoretically superior to hormone replacement. (2) Limited Western validation remains the key limitation. (3) Safety profile appears excellent based on 15+ years of use in Russia. (4) Best evidence is for patients with age-related melatonin decline. GAPS: No Western RCTs. Mechanism of action at molecular level not fully elucidated. Optimal patient selection criteria unknown. Duration of benefit after completing a course. Bioavailability of oral peptide (dipeptide may survive GI transit). ACTIVE TRIALS: No registered trials on ClinicalTrials.gov. Research ongoing at St. Petersburg Institute of Bioregulation and Gerontology.